Correlation Between C4 Therapeutics and Virax Biolabs

Can any of the company-specific risk be diversified away by investing in both C4 Therapeutics and Virax Biolabs at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining C4 Therapeutics and Virax Biolabs into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between C4 Therapeutics and Virax Biolabs Group, you can compare the effects of market volatilities on C4 Therapeutics and Virax Biolabs and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in C4 Therapeutics with a short position of Virax Biolabs. Check out your portfolio center. Please also check ongoing floating volatility patterns of C4 Therapeutics and Virax Biolabs.

Diversification Opportunities for C4 Therapeutics and Virax Biolabs

0.3

Correlation Coefficient

C4 Therapeutics  Virax Biolabs

Weak diversification

The 3 months correlation between CCCC and Virax is 0.3. Overlapping area represents the amount of risk that can be diversified away by holding C4 Therapeutics and Virax Biolabs Group in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Virax Biolabs Group and C4 Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on C4 Therapeutics are associated (or correlated) with Virax Biolabs. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Virax Biolabs Group has no effect on the direction of C4 Therapeutics i.e., C4 Therapeutics and Virax Biolabs go up and down completely randomly.

Pair Corralation between C4 Therapeutics and Virax Biolabs

Given the investment horizon of 90 days C4 Therapeutics is expected to under-perform the Virax Biolabs. But the stock apears to be less risky and, when comparing its historical volatility, C4 Therapeutics is 3.48 times less risky than Virax Biolabs. The stock trades about -0.04 of its potential returns per unit of risk. The Virax Biolabs Group is currently generating about 0.09 of returns per unit of risk over similar time horizon. If you would invest  80.00  in Virax Biolabs Group on September 3, 2024 and sell it today you would earn a total of  117.00  from holding Virax Biolabs Group or generate 146.25% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

C4 Therapeutics  vs.  Virax Biolabs Group

C4 Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days C4 Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's fundamental indicators remain rather sound which may send shares a bit higher in January 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Virax Biolabs Group

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Virax Biolabs Group has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with C4 Therapeutics and Virax Biolabs

The main advantage of trading using opposite C4 Therapeutics and Virax Biolabs positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if C4 Therapeutics position performs unexpectedly, Virax Biolabs can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Virax Biolabs will offset losses from the drop in Virax Biolabs' long position.

The idea behind C4 Therapeutics and Virax Biolabs Group pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.